FATE
Price
$2.32
Change
+$0.02 (+0.87%)
Updated
Oct 2 closing price
Capitalization
285.17M
27 days until earnings call
Intraday BUY SELL Signals
REPL
Price
$13.07
Change
-$0.38 (-2.83%)
Updated
Oct 2 closing price
Capitalization
1.18B
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs REPL

FATE vs REPL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FATE vs. REPL commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and REPL is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
FATE vs REPL: Fundamental Ratings
FATE
REPL
OUTLOOK RATING
1..100
4515
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3836
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (28) in the Biotechnology industry is in the same range as REPL (54). This means that FATE’s stock grew similarly to REPL’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as REPL (100). This means that FATE’s stock grew similarly to REPL’s over the last 12 months.

FATE's SMR Rating (98) in the Biotechnology industry is in the same range as REPL (99). This means that FATE’s stock grew similarly to REPL’s over the last 12 months.

REPL's Price Growth Rating (36) in the Biotechnology industry is in the same range as FATE (38). This means that REPL’s stock grew similarly to FATE’s over the last 12 months.

REPL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as FATE (100). This means that REPL’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEREPL
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
88%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 8 days ago
83%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (FATE: $2.30 vs. REPL: $13.45)
Brand notoriety: FATE and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 48% vs. REPL: 43%
Market capitalization -- FATE: $285.17M vs. REPL: $1.18B
FATE [@Biotechnology] is valued at $285.17M. REPL’s [@Biotechnology] market capitalization is $1.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green while REPL’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 0 green, 5 red.
According to our system of comparison, FATE is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 2 TA indicator(s) are bullish while REPL’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 2 bullish, 4 bearish.
  • REPL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, REPL is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -1.29% price change this week, while REPL (@Biotechnology) price change was +6.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

FATE is expected to report earnings on Oct 29, 2026.

REPL is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
FATE
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KLAG28.701.40
+5.14%
Leverage Shares 2x Long KLAC Daily ETF (KLAG)
VGIT56.64-0.02
-0.04%
Vanguard Intermediate-Term Treasury ETF (VGIT)
MPRO31.39-0.03
-0.10%
Monarch ProCap Index ETF (MPRO)
ENZL44.89-0.19
-0.41%
iShares MSCI New Zealand ETF (ENZL)
PML6.48-0.09
-1.37%
PIMCO Municipal Income FUND II

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with NKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.95%
NKTX - FATE
45%
Loosely correlated
-2.29%
VCYT - FATE
44%
Loosely correlated
-4.02%
PTN - FATE
41%
Loosely correlated
+2.14%
CYTK - FATE
39%
Loosely correlated
-0.44%
REPL - FATE
39%
Loosely correlated
+1.59%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+1.59%
IMNN - REPL
57%
Loosely correlated
+2.33%
SNDX - REPL
49%
Loosely correlated
-3.09%
KYMR - REPL
45%
Loosely correlated
-1.49%
NRIX - REPL
43%
Loosely correlated
-1.56%
ZYME - REPL
42%
Loosely correlated
-2.00%
More